{
  "id": 8265194,
  "title": "Palomar Labs Spins Out Ariadne Bio to Advance Non-Hallucinogenic Therapy for Parkinson’s Apathy",
  "url": "https://urgent.news/2026/09/18/palomar-labs-spins-out-ariadne-bio-to-advance-non-hallucinogenic",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-18T15:11:45.000Z",
  "source": {
    "name": "GEN Biotechnology",
    "slug": "gen-biotechnology",
    "url": "https://www.genengnews.com/topics/drug-discovery/palomar-labs-spins-out-ariadne-bio-to-advance-non-hallucinogenic-therapy-for-parkinsons-apathy/"
  },
  "original_language": "en",
  "account": "Palomar Labs, a venture studio, has spun out its first portfolio company, Ariadne Bio, to advance the development of a non-hallucinogenic therapy for Parkinson's disease apathy. The new company's lead program, AB-300, is a clinical-stage molecule that functions as a serotonin 2A receptor agonist. Ariadne Bio's CEO, Shlomi Raz, explained that the drug is being developed to restore motivation in people with Parkinson's, a condition that affects approximately 40% of those with the disease in mid to late stages. Raz noted that while apathy and depression have some overlapping features, they are distinct conditions and current therapies for depression may worsen apathy. AB-300 is unique in that it does not act on dopamine receptors, unlike many existing treatments for mental stimulation, which can be poorly tolerated by older adults. The company is actively exploring other indications for apathy in aging populations.",
  "summary": "Backed by preclinical data and funding from The Michael J. Fox Foundation, Ariadne Bio is advancing AB-300, a serotonin 2A receptor agonist, as a potential treatment for Parkinson’s-related apathy. The post Palomar Labs Spins Out Ariadne Bio to Advance Non-Hallucinogenic Therapy for Parkinson’s Apathy appeared first on GEN - Genetic Engineering and Biotechnology News .",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}